Geographic atrophy

Retinitis pigmentosa
#American Academy of Ophthalmology 2022 #Dry AMD #Gene therapy #Geographic atrophy #Ophthalmology #Retinitis pigmentosa

Janssen shares ‘encouraging’ gene therapy study results

Results from Phase I/II MGT009 study into investigational gene therapy botaretigene sparoparvovec suggest sustained vision improvement in patients with X-linked retinitis pigmentosa (XLRP).  The study found treatment with botaretigene sparoparvovec had an acceptable safety profile and demonstrated encouraging improvements in retinal sensitivity, visual function and functional… Read More

#News

#Complement Therapeutics #Dry AMD #Gene therapy #Geographic atrophy #Scientific Advisory Board

Complement Therapeutics announces SAB to drive pipeline

Biotechnology company Complement Therapeutics (CTx) has formed a Clinical & Scientific Advisory Board to help accelerate the development of its pipeline of therapeutics targeting complement-mediated diseases. The company’s lead investigational product, CTx001, is a gene therapy for dry age-related macular degeneration/geographic atrophy, which is a leading cause of blindness. The… Read More

#News